AMLX
NASDAQ · Pharmaceuticals
Amylyx Pharmaceuticals Inc
$13.47
-0.06 (-0.44%)
Financial Highlights (FY 2026)
Revenue
140.51M
Net Income
-485,264,659
Gross Margin
63.2%
Profit Margin
-345.4%
Rev Growth
+574.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 63.2% | 63.8% | 63.8% | 63.8% |
| Operating Margin | -360.2% | 19.1% | 17.1% | 16.6% |
| Profit Margin | -345.4% | 14.3% | 15.6% | 14.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 140.51M | 449.35M | 403.13M | 461.04M |
| Gross Profit | 88.83M | 286.71M | 257.22M | 294.17M |
| Operating Income | -506,145,089 | 85.79M | 69.14M | 76.52M |
| Net Income | -485,264,659 | 64.17M | 62.78M | 65.03M |
| Gross Margin | 63.2% | 63.8% | 63.8% | 63.8% |
| Operating Margin | -360.2% | 19.1% | 17.1% | 16.6% |
| Profit Margin | -345.4% | 14.3% | 15.6% | 14.1% |
| Rev Growth | +574.3% | +13.9% | +9.9% | +10.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 314.80M | 303.04M | 267.92M |
| Total Equity | — | 1.08B | 939.99M | 1.02B |
| D/E Ratio | — | 0.29 | 0.32 | 0.26 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -506,644,708 | 107.91M | 96.37M | 106.13M |
| Free Cash Flow | — | 81.20M | 53.03M | 80.72M |